VMRC-RCZ
CAD$759.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The VMRC-RCZ cell line is a human renal cell carcinoma (RCC) line established from a patient with clear cell type kidney cancer. It was derived to investigate the biological and genetic underpinnings of renal carcinogenesis, particularly with regard to chromosomal abnormalities and tumor progression. Cytogenetic analysis of VMRC-RCZ has revealed deletion of the short arm of chromosome 9, specifically within the 9p21-22 region. This deletion implicates the loss of key tumor suppressor genes such as CDKN2A, which is commonly associated with various malignancies and plays a role in cell cycle regulation. In broader cancer genome analyses, VMRC-RCZ has contributed to the mapping of homozygous deletions across multiple tumor types. These studies show that regions like 9p21 often exhibit structural instability in cancer cell lines, including VMRC-RCZ, suggesting that genomic deletions in this region may confer a selective growth advantage during tumor evolution. Additionally, VMRC-RCZ has been incorporated into high-resolution genomic profiling platforms for the systematic identification of cancer-related mutations and copy number alterations, making it a valuable model for studying RCC pathogenesis and for the exploration of potential therapeutic vulnerabilities in renal malignancies. |
|---|---|
| Organism | Human |
| Tissue | Kidney |
| Disease | Renal cell carcinoma |
| Metastatic site | Renal |
| Synonyms | VMRCRCZ, Virginia Mason Research Center-Renal Cancer Z |
Characteristics
| Age | Age unspecified |
|---|---|
| Gender | Sex unspecified |
| Ethnicity | Caucasian |
| Growth properties | Adherent |
Regulatory Data
| Citation | VMRC-RCZ (Cytion catalog number 305886) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1791 |
Biomolecular Data
| Mutational profile | Mutation: TP53, Simple, p.Asp48Valfs*74 (c.143_146del4), Heterozygous (Cosmic-CLP=909781), VHL, Simple, c.463+2T>C, Heterozygous, Note=Splice donor mutation (Cosmic-CLP=909781) |
|---|
Handling
| Culture Medium | EMEM (MEM Eagle), w: 2 mM L-Glutamine, w: 2.2 g/L NaHCO3, w: EBSS (Cytion article number 820100a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Split ratio | A ratio of 1:6 is recommended. |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305886-041125 | Certificate of Analysis | 05. Dec. 2025 | 305886 |